References
- Himmelhoch J M. On the usefulness of clinical case studies. Bipolar Disorders 2003; 5: 69–71
- Boyce P, Ellis P, Penrose-Wall J. Australian and New Zealand Clinical Practice Guidelines for specialist adult mental health care: an introduction. Australasian Psychiatry 2003; 11: 21–25
- Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's Wort) in major depressive disorder. A randomised controlled trial. Journal of the American Medical Association 2002; 287: 807–814
- Schneider L S, Nelson J G, Clary C M, et al. An eight-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. American Journal of Psychiatry 2003; 160: 1277–1285
- Carroll B J. Sertraline and the Cheshire Cat in geriatric depression. American Journal of Psychiatry 2004; 161: 759
- Bowden C L, Calabrese J R, McElroy S L, et al. A randomized, placebo-controlled 12-month trial of Divalproex and Lithium in treatment of outpatients with Bipolar I Disorder. Archives of General Psychiatry 2000; 57: 481–489
- Kirsch I, Moore T J, Scoboria A, et al. The Emperor's new drugs: An analysis of antidepressant medication data, submitted to the US Food and Drug Administration. Prevention and Treatment 2002; 5: 1–11
- Khan A, Khan S, Brown W A. Are placebo controls necessary to test new antidepressants and anxiolytics?. International Journal of Neuropsychopharmacology 2002; 5: 193–197
- Williams J W, Jr, Mulrow C D, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary: Clinical Guidelines, Part 2. Annals of Internal Medicine 2000; 132: 743–756
- Anderson I M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. Journal of Affective Disorders 2000; 58: 19–36
- Robinson D S, Rickels K. Concerns about clinical drug trials. Journal of Clinical Psychopharmacology 1992; 20: 593–596
- DHHS Depression Guideline Panel. Depression in primary care: volume 2. Treatment of major depression. Clinical practice guideline, number 5. US Department of Health and Human Services, Rockville, MD 1993, AHCPR. Publication no. 93–0551
- Elkin I, Shea T, Watkins J T, et al. National Institute of Mental Health treatment of depression collaborative research program. Archive of General Psychiatry 1989; 46: 971–982
- Parker G, Roy K, Eyers K. Cognitive behavior therapy for depression? Choose horses for courses. American Journal of Psychiatry 2003; 160: 825–834
- Holmes J. All you need is cognitive behaviour therapy. British Medical Journal 2002; 324: 288–294
- Parker G. ‘New’ and ‘old’ antidepressants: all equal in the eyes of the lore?. British Journal of Psychiatry 2001; 179: 95–96
- Parker G, Anderson I M, Haddad P. Clinical trials of antidepressant medications are producing meaningless results. British Journal of Psychiatry 2003; 83: 102–194
- Parker G. Depressions black and blue: changing the Zeitgeist. Medical Journal of Australia 2003; 179: 335–336
- Walsh B T, Seidman S N, Sysko R, et al. Placebo response in studies of major depression: Variable, substantial, and growing. Journal of the American Medical Association 2002; 287: 1840–1847
- Glassman A H, Roose S P. Delusional depression: a distinct clinical entity. Archives of General Psychiatry 1981; 38: 424–427
- Anton R F, Jr, Burch E A, Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. American Journal of Psychiatry 1990; 147: 1203–1208
- Fairchild C J, Rush A J, Vasavada N, et al. Which depressions respond to placebo?. Psychiatry Research 1986; 18: 217–226
- Peselow E D, Sanfilipo M P, Difiglia C, et al. Melancholic/endogenous depression and response to somatic treatment and placebo. American Journal of Psychiatry 1992; 149: 1324–1334
- Robinson L, Berman J, Neimeyer R. Psychotherapy for the treatment of depression: a comprehensive review of controlled outcome research. Psychological Bulletin 1990; 108: 30–49
- Luby E D, Singareddy R K. Long-term therapy with lithium in a private practice clinic: a naturalistic study. Bipolar Disorders 2003; 5: 62–68
- Wells K B. Treatment research at the crossroads. The scientific interface of Clinical trials and effectiveness research. American Journal of Psychiatry 1999; 156: 5–10
- Parker G. Classifying depression: should paradigms lost be regained?. American Journal of Psychiatry 2000; 157: 1195–1203
- Spiker D G, Weiss J C, Dealy R S, et al. Psychotic (delusional) depression: a meta-analysis of physical treatments. Journal of Affective Disorders 1985; 24: 17–24
- Parker G, Roy K, Hadzi-Pavlovic D, Pedic F. Psychotic (delusional) depression: a meta-analysis of physical treatments. Journal of Affective Disorders 1992; 24: 17–24
- Parker G. Differential effectiveness of newer and older antidepressants appears mediated by an age effect on the phenotypic expression of depression. Acta Psychiatrica Scandinavica 2002; 106: 168–170
- Joyce P R, Mulder R T, Luty S E, et al. A differential response to nortriptyline and fluoxetine in melancholic depression: the importance of age and gender. Acta Psychiatrica Scandinavica 2003; 108: 20–23
- Ellis P M, Hickie I A, Smith DA R. Summary of guidelines for the treatment of depression. Australasian Psychiatry 2003; 11: 34–38
- Meltzer H. Neuropsychpharmacology in the media: Did they get it right?. CINP Newsletter 2004; 1–18, March